Skip to content

News Category: Health & Medical

Mediterranean diet improves immunotherapy response rates and progression-free survival in advanced melanoma, new study presented at UEG Week suggests

By asianet

Eating a Mediterranean diet, rich in fibre, mono-unsaturated fatty acids and polyphenols, has been associated with improved immunotherapy response rates and progression-free survival in advanced melanoma patients, a new study presented today at UEG Week 2022 has found. Experts anticipate that the diet will play an important role in the success of immunotherapy and trials … Continued

Synapse Medicine Initiates Multi-Site Implementation Study with Leading U.S Hospitals

By asianet

• Synapse Medicine clinical decision support technology analyzes drug-related risks based on each patient’s clinical characteristics and will be studied for its impact on inpatient pharmacist efficacy and efficiency. • The Synapse Medicine medication reconciliation tool will be deployed through an integration with the hospitals’ current EPIC EHR workflow. • The study also has potential … Continued

TauRx Announces Results from Phase 3 Alzheimer’s Disease Study, LUCIDITY, Assuring Path for Regulatory Submissions

By asianet

– For people with early Alzheimer’s (MCI), HMTM treatment resulted in sustained improvement in cognition over pre-treatment baseline, and normalisation of brain atrophy to a rate similar to healthy individuals – For people with mild to moderate Alzheimer’s, HMTM stabilised cognition and function and reduced rate of brain atrophy compared to historical matched individuals with … Continued

Servier unveils its 2030 ambition and reveals a new visual identity

By asianet

A new ambition by 2030 to accelerate its transformation dynamic A visual identity, a marker of the successful transformation of the Group, its ambitions and its renewal Servier today unveils its 2030 ambition as well as a new visual identity that reflects the transformation undertaken by the Group, bringing visible results. The Group intends to … Continued

Global Milk Industry Digestibility Breakthrough

By asianet

–World-first Haelen technology achieves 100% fresh, natural milk that is twice as digestible Naturo, the company behind the world-first patented ‘Haelen’ milk processing technology which gives fresh milk a 60-day shelf life has achieved another significant breakthrough in the global milk market, this time for digestibility. Haelen technology is the biggest development in the global … Continued

Cambrex Announces Stability Storage Expansions in Ireland and Belgium

By asianet

Cambrex today announced the expansion of their stability storage business, Q1 Scientific, which offers environmentally-controlled stability storage services to the pharmaceutical, medical device and life sciences industries. Q1 Scientific will open a new 20,000-square-foot cGMP facility in Belgium and add an additional 10,000 square feet at their existing facility in Waterford, Ireland. The expansions will … Continued

Hayashibara Brings Back “Trehalose Symposium” to Reveal Its Game-changing Versatilities in Human Biochemistry

By asianet

Hayashibara Co., Ltd., a member of Nagase Group and headquartered in Okayama City, western Japan, hosted the 24th Trehalose Symposium, with the support of the Japanese Society of Applied Glycoscience, on September 8, 2022. Photo: https://kyodonewsprwire.jp/prwfile/release/M104815/202209297422/_prw_PI1fl_JX2ftzQv.png This highly specialized academic event returned to Tokyo after a three-year hiatus, engaging 231 attendees in person and online … Continued

ABILITY DIABETES GLOBAL – A Landmark RCT in the field of PCI for patients with DM, completes Enrolment

By asianet

ABILITY DIABETES-GLOBAL [https://www.conceptmedical.com/clinical-program/ability-diabetes-global/](ADG), is the World’s largest Randomized Controlled Trial (RCT) for patients with DM (Diabetes Mellitus), comparing head-to-head the Sirolimus eluting stent , Abluminus DES+ (Concept Medical Inc.[https://www.conceptmedical.com/]) with the XIENCE family of DES (Abbott Cardiovascular). Diabetes has been the Achilles heel for any vascular interventional procedures and there is a clinical need for … Continued

Pharming Announces US FDA Acceptance for Priority Review of its New Drug Application for Leniolisib

By asianet

The FDA has assigned a PDUFA goal date of March 29, 2023 for the NDA submission based on randomized-controlled and long-term extension data for leniolisib as a treatment for APDS, a rare primary immunodeficiency Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM) (Nasdaq: PHAR) announces that the US Food and Drug Administration (FDA) … Continued